Camrelizumab for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study is testing a drug called camrelizumab (an immunotherapy that helps your immune system fight cancer) in people with advanced esophageal cancer. The goal is to see how well it works in real-life settings, either alone or combined with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced esophageal cancer that cannot be removed with surgery, has come back, or has spread.
- You are 18 years or older.
- Your doctor believes you can receive the study drug camrelizumab, alone or with other treatments.
- You are not pregnant or breastfeeding.
- You are not currently in another blinded clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving the immunotherapy drug camrelizumab together with chemotherapy before surgery can help people with esophageal cancer avoid needing full removal of the esophagus. It aims to preserve the esophagus while still treating the cancer effectively.
This trial tests a combination of an immunotherapy drug (camrelizumab) with chemotherapy and radiation to shrink advanced rectal cancer before surgery. The goal is to help more patients have successful surgery with complete tumor removal.
This study tests whether adding camrelizumab (an immune therapy) to chemotherapy—after a stent is placed to open a blocked left-sided colon—improves outcomes. It’s meant for people whose cancer can still be removed with surgery after the blockage is treated.
This trial tests combining the immunotherapy drug camrelizumab with chemotherapy and radiation before and after surgery for a specific type of stomach-esophagus cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
This study tests whether adding camrelizumab (an immune treatment) to standard chemoradiotherapy can control advanced esophageal squamous cell cancer. It is meant for people who have not had any prior whole-course cancer medicines for this cancer stage.
This trial tests a combination of radiation, chemotherapy (cisplatin and paclitaxel), and an immunotherapy drug called camrelizumab for patients with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if adding immunotherapy improves outcomes compared to standard treatment alone.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.